Improving the model for the uk ms disease modifying treatment risk sharing scheme analysis: a new natural history dataset.
Although in 2002 the National Institute for Clinical Excellence, in 2002, concluded that the disease modifying treatments (DMTs) for MS-interferon-b and glatiramer acetate-were not cost effective over the short-term, it was recognised that longer-term benefits were possible. The 'UK risk sharin...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|